Yilmaz, Musa http://orcid.org/0000-0002-4498-4895
Kantarjian, Hagop http://orcid.org/0000-0002-1908-3307
Ravandi, Farhad http://orcid.org/0000-0002-7621-377X
Article History
Received: 26 April 2021
Revised: 3 June 2021
Accepted: 4 June 2021
First Online: 30 June 2021
Competing interests
: FR received advisory/honoraria and research funding from Syros Pharmaceuticals. MY and HK has no competing interests.